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Cells of the innate immune system act in synergy to provide a first line of defense against pathogens. Here we describe
that dendritic cells (DCs), matured with viral products or mimics thereof, including Epstein-Barr virus (EBV), activated
natural killer (NK) cells more efficiently than other mature DC preparations. CD56
brightCD16
  NK cells, which are
enriched in human secondary lymphoid tissues, responded primarily to this DC activation. DCs elicited 50-fold stronger
interferon-c (IFN-c) secretion from tonsilar NK cells than from peripheral blood NK cells, reaching levels that inhibited B
cell transformation by EBV. In fact, 100- to 1,000-fold less tonsilar than peripheral blood NK cells were required to
achieve the same protection in vitro, indicating that innate immune control of EBV by NK cells is most efficient at this
primary site of EBV infection. The high IFN-c concentrations, produced by tonsilar NK cells, delayed latent EBV antigen
expression, resulting in decreased B cell proliferation during the first week after EBV infection in vitro. These results
suggest that NK cell activation by DCs can limit primary EBV infection in tonsils until adaptive immunity establishes
immune control of this persistent and oncogenic human pathogen.
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Introduction
Epstein-Barr (EBV) is a lymphotropic c-herpes virus
infecting over 90% of the human adult population [1,2]. A
striking feature that the virus shares with other c-herpes
viruses is its oncogenic potential. This transforming property
can be observed in vitro and in vivo both in immunocompe-
tent and more frequently in immunosuppressed individuals.
In the latter group, EBV causes tumors such as post-
transplant lymphoproliferative disease and immunoblastic
lymphoma, whereas, nasopharyngeal carcinoma, Hodgkin’s
disease and endemic Burkitt’s lymphoma are the most
prominent EBV-associated malignancies in immunocompe-
tent individuals [3]. However, in most individuals, the lifelong
chronic infection with EBV is fortunately free of complica-
tions due to effective immune control, primarily mediated by
CD4
þ and CD8
þ T cells [4]. In addition to protective T cell
immunity in healthy virus carriers, several lines of evidence
suggest a role for innate lymphocytes in the resistance against
EBV-associated malignancies. Firstly, in male patients with X-
linked lymphoproliferative disease (XLP), who frequently
succumb after primary EBV infection to EBV-induced
lymphomas, a mutation in the SAP gene leads to defective
recognition of EBV-transformed B cells by NK cells [5–7].
While SAP mutations not only affect NK cell function, this
defective recognition most likely contributes to loss of EBV-
speciﬁc immune control. Secondly, IL-2-activated peripheral
blood NK cells have been shown to restrict EBV-induced B
cell transformation in vitro [8–10]. Thirdly, NK cell depletion
from PBMCs prior to adoptive transfer into SCID mice,
rendered the animals more susceptible to tumor develop-
ment after transfer of EBV-transformed B cells [11]. Fourthly,
activated NK cells have been shown to lyse lytically EBV
replicating B cells [12]. Fifthly, a novel primary immunode-
ﬁciency with a speciﬁc NK cell defect was recently reported to
be associated with EBV-driven lymphoproliferative disease
[13]. Therefore, NK cells may be involved in the early phase of
the EBV-speciﬁc immune response.
NK cells are innate lymphocytes that play an important
role in the control of infections and the immune surveillance
of tumors [14]. In particular, early after primary viral
infections they are thought to limit the viral burden until
virus-speciﬁc T cells are able to eliminate the infection or
control viral titers at low levels [15]. During infection with the
b-herpes virus murine cytomegalovirus (MCMV), NK cells
have been shown to be crucial for limiting viral replication
[16]. Indeed, lack of the activating NK cell receptor Ly49H,
involved in the recognition of the MCMV m157 protein,
confers susceptibility to fatal MCMV infection in BALB/c
mice, whereas Ly49H-expressing C57BL/6 mice survive
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need to receive additional signals to successfully protect
against MCMV infection and these are provided by DCs [18–
22]. Notably, NK cells produce cytokines such as IFN-c,
proliferate and increase their cytotoxicity upon activation by
both myeloid and plasmacytoid DCs [23]. Therefore, DCs
seem to activate NK cells early after infection in order to
restrict pathogen replication until the adaptive immune
system establishes long-lasting immune control.
Although there are signiﬁcant similarities between murine
and human NK cell activation by DCs, human and mouse NK
cell phenotypes and functions differ substantially and these
differences also inﬂuence NK cell/DC interactions. Two main
functional NK cell subsets have been distinguished in humans:
CD56
dimCD16
þNK cells readily lyse susceptible target cells, but
secrete only low levels of cytokines after activation. In contrast,
CD56
brightCD16
  NK cells produce large amounts of cytokines
uponstimulation and acquire cytotoxicity only after prolonged
activation [24,25]. Around 90% of human peripheral blood NK
cells are CD56
dimCD16
þ, whereas CD56
brightCD16
  NK cells
constitute less than 10% of the peripheral blood NK cell pool.
However, in secondary lymphoid organs such as tonsils and
lymph nodes, the CD56
brightCD16
  NK cells are the dominant
subset [26–28]. Interestingly, human DCs primarily activate this
NK cell subset [29,30]. Because the tonsils are the primary site
of EBV infection, we investigated whether the DC/NK cell
crosstalk could trigger NK cells to limit B cell transformation
during EBV infection.
We show here that human NK cells from peripheral blood,
spleen, and tonsils limit the outgrowth of EBV-infected B
cells after activation by DCs in vitro. Monocyte-derived DCs,
which were matured with viral double-stranded RNA or its
analog polyinosine-polycytidylic acid (polyI:C) to produce
high levels of IL-12, stimulated strong IFN-c secretion and
proliferation of mainly the CD56
brightCD16
  NK cell subset.
These NK cells then signiﬁcant restricted B cell trans-
formation by EBV. Tonsilar NK cells were more efﬁcient in
inhibiting EBV-induced B cell transformation in vitro than
peripheral blood NK cells and secreted high IFN-c levels,
which proved sufﬁcient to limit B cell-transformation despite
their low frequency at the site of primary infection.
Restriction of B cell transformation by EBV was primarily
due to IFN-c secretion by DC-activated NK cells, and due to
regulation of the EBV latency program by this cytokine.
Interestingly, myeloid DCs, matured by exposure to EBV,
were also able to elicit IFN-c secretion by NK cells to levels
protective against EBV-induced B cell transformation. Con-
trary to the original hypothesis that NK cells control
pathogens via spontaneous cytotoxicity, which gave rise to
the name of this innate lymphocyte subset, we demonstrate
that these NK cell responses require activation by DCs and
are mediated by cytokines. These data provide the ﬁrst
evidence for a direct antiviral effector function of NK cells in
secondary lymphoid tissues, which might limit EBV infection
until the adaptive immune system efﬁciently controls it.
Results
NK Cell Activation by Differently Matured DCs
The outcome of the crosstalk between NK cells and DCs
depends strongly on the activation status of both cell types
[27]. We investigated how differently matured human mono-
cyte-derived DCs vary in their capacity to elicit proliferation
and IFN-c secretion by NK cells in order to deﬁne the optimal
activation conditions for anti-viral NK cell responses. DCs
were matured using a standard mixture of proinﬂammatory
cytokines (IL-1b, IL-6, TNF-a and PGE2: cyt DC), the TLR3
and mda-5 ligand polyI:C (polyI:C DC), and the TLR4 ligand
LPS (lps DC). In addition, DCs were matured with poly I:C
supplemented with proinﬂammatory cytokines (IL-1b and
TNF-a) and type I and II interferons (DC1) to generate DC1
cells according to Mailliard and colleagues [31]. As expected,
all of these maturation stimuli were able to signiﬁcantly up-
regulate MHC class II and costimulatory molecules such as
CD80, CD83 and CD86 (Table S1). However, when we
compared different DC preparations for their capacity to
activate NK cells from peripheral blood, we found that DCs
matured with polyI:C were far superior in NK cell activation
compared to the other DC preparations (Figure 1A). polyI:C
DCs and DC1s induced strong proliferation with 40–75% of
the NK cells cycling after 6 days. Further characterization
showed that the number of NK cells producing IFN-c
increased signiﬁcantly (4-fold to 10-fold), when they were
activated by polyI:C DCs and DC1s compared to immature
DCs (iDCs) or cyt DCs, respectively (Figure 1B). In line with
previous ﬁndings, the CD56
brightCD16
  NK cells were
preferentially stimulated by these DC preparations to
proliferate and secrete IFN-c (Figure 1). These data demon-
strate that DCs matured by polyI:C are efﬁcient stimulators of
CD56
bright CD16
  NK cells, the NK cell subset enriched in
human secondary lymphoid tissues.
Production of NK Cell Stimulatory Cytokines upon DC
Maturation with Viral Stimuli
To characterize the mechanism of DC-mediated NK
activation, we compared the production of NK cell stimula-
tory cytokines by DCs after maturation. Previous work
indicated important roles for IL-12, IL-15, and IL-18 in the
activation of NK cell proliferation and IFN-c secretion
[28,32]. We detected only little (,50 pg/ml) or no secretion
of the bioactive form of IL-12 (IL-12p70) by cyt DCs or iDCs,
respectively, whereas polyI:C DCs and DC1s produced high
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Author Summary
Epstein-Barr virus (EBV) establishes a persistent infection in nearly all
human adults. Due to its tumor causing potential EBV infection has
to be continuously controlled by the immune system in virus
carriers. We demonstrate here that in the first week after infection,
when other EBV-specific immune responses are still being recruited,
human natural killer (NK) cells are able to prevent transformation of
the main host cell type by EBV, the human B cell. Especially NK cells
of tonsils, the primary site of EBV infection, inhibit B cell
transformation by EBV after they have been activated by dendritic
cells (DCs). For this protective function, EBV can directly stimulate
DCs to efficiently activate NK cells. Interestingly, NK cells primarily
prevent B cell transformation by EBV via secretion of the anti-viral
cytokine IFN-c, and NK cells from tonsils and lymph nodes produce
5-fold more of this cytokine than their peripheral blood counter-
parts. These data suggest that specialized NK cells in tonsils, the
mucosal entry site of EBV, can be efficiently stimulated by EBV-
activated DCs, and then limit EBV-induced B cell transformation until
EBV-specific immune control by other components of the immune
system is established.amounts of this cytokine (up to 5000 pg/ml) (Table 1). LPS-
matured DCs produced intermediate amounts of IL-12p70.
Monocyte-derived DCs matured with EBV-derived dsRNA
produced slightly higher IL-12 levels than LPS matured DCs
(up to 200pg/ml). Addition of recombinant IL-12p70 at
comparable levels ( 100pg/ml) induced both proliferation
and IFN-c production by NK cells (data not shown). IL-15
secretion and surface expression of IL-15 and IL-15Ra were
also primarily induced by incubation of DCs with polyI:C
(Tables 1 and S1). IL-18 secretion was not detectable for all
DC preparations tested (Table 1). In line with these
observations, IFN-c secretion of NK cells stimulated by
DC1s was mainly dependent on IL-12 (80%, p , 0.01) and
to a lesser degree on IL-18 (15%, p , 0.05) (Figure S1A).
Similar results were obtained with polyI:C DCs (data not
shown). Consistent with the hypothesis that polyI:C-matured
DCs mainly elicited IFN-c secretion of NK cells via their high
levels of secreted IL-12, this NK cell/DC interaction was not
sensitive to transwell separation (Figure S1B). Furthermore,
we found that NK cell proliferation upon coculture with
DC1s (Figure S1C) and polyI:C DCs (data not shown) could be
blocked with an IL-12 speciﬁc antibody by 90% or 80%,
respectively (p , 0.01 for both), and again transwell experi-
ments showed that direct cell contact was not required (data
not shown). Blocking of IL-15 also signiﬁcantly decreased
numbers of surviving NK cells when combined with anti-IL-
12 antibodies (p , 0.01), however blocking of IL-15 or IL-18
alone did not signiﬁcantly decrease survival (Figure S1D). In
addition, antibody blocking of IL-2 did not inﬂuence DC
induced proliferation and IFN-c production by NK cells
Figure 1. DCs Activate NK Cells Most Efficiently after Maturation with the dsRNA Analog polyI:C
Differently matured DCs were compared to immature DCs for their ability to induce peripheral blood NK cell proliferation (A) and IFN-c secretion (B).
The tested maturation stimuli included (i) the standard proinflammatory cytokine cocktail consisting of IL-1b, IL-6, TNF-a, and prostaglandin E2 (cyt DC);
(ii) the TLR3 and mda-5 agonist polyI:C (polyI:C DC); (iii) a cocktail of inflammatory cytokines (IL-1b, TNF-a IFN-a, IFN-c) and polyI:C (DC1); (iv) the TLR4
agonist LPS (lps DC). These differently matured DCs were compared to immature DCs (iDC) and stimulation with IL-2 alone.
(A) CFSE-labeled NK cells and DCs were cultured for 6d at a ratio of 5:1, and proliferation was analyzed by gating on CD3
 CD56
þ cells. Percentages of
CFSE dilute CD16
þ and CD16
  NK cells are indicated.
(B) NK cells and DCs were cultured for 20 h at a ratio of 2:1 and BFA was added for the last 8 h. IFN-c production of CD3
 CD56
þ cells was analyzed.
Percentages of IFN-c positive NK cells are indicated. Similar results were obtained in three independent experiments.
doi:10.1371/journal.ppat.0040027.g001
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NK Cells Limit EBV Infection(Figure S2). These data suggest that polyI:C and EBV-derived
dsRNA elicit IL-12 production, which in turn stimulates NK
cell proliferation and IFN-c production by NK cells.
Restriction of EBV-induced B Cell Transformation by NK
Cells upon Activation by polyI:C Matured DCs
In contrast to previous studies focusing on IL-2 activation
of NK cells, we addressed the question whether NK cells
restrict EBV-induced B cell transformation after activation
by cells of the innate immune system. Because interactions
between NK cells and DCs have been shown to be essential for
virus control in murine models of herpes virus infections
[19,33,34], we speciﬁcally investigated whether DCs can
activate NK cells to limit EBV-mediated B cell transforma-
tion. For these experiments we used monocyte-derived DCs,
since they can be generated at sufﬁcient numbers to allow
functional experiments. When we infected puriﬁed B cells
with EBV and cocultured them with resting puriﬁed
peripheral blood NK cells at ratios of 5:1 (NK to B cells) we
could not observe any restriction of B cell transformation.
Similarly, addition of iDCs or cyt DCs induced only limited
NK cell-mediated inhibition of EBV-transformed B cell
outgrowth (6 or 13%, respectively) (Figure 2A–2C). However,
in cultures with NK cells and polyI:C DCs or DC1s, we
observed a 49 or 55% (both p , 0.01) reduction of the
number of transformed B cells, respectively (Figure 2B and
2 C ) .T h eD Cp r e p a r a t i o n su s e di nt h i ss t u d yh a dn o
signiﬁcant direct effect on B cell transformation by EBV
(data not shown). This demonstrated that DC-activated NK
cells can inhibit B cell transformation by EBV.
Low Numbers of Tonsilar NK Cells Restrict EBV-Induced B
Cell Transformation
Tonsils are the primary infection sites for EBV and harbor
enriched populations of CD56
brightCD16
  NK cells, which can
be efﬁciently activated by DCs. Therefore, we investigated
whether tonsilar NK cells can restrict EBV-induced B cell
transformation. For this purpose, we depleted tonsilar
mononuclear cells of CD3
þ T cells by cell sorting and
compared the numbers of transformed B cells after EBV
infection to cultures that were depleted of both CD3
þ T and
CD56
þ NK cells (Figure 2D and 2E). Without addition of DCs
and with the addition of allogeneic iDCs or cyt DCs, we did
not observe any signiﬁcant difference in the number of
transformed B cells after 12 days (Figure 2D and 2E).
However, we observed a 35% or 42% (p , 0.03 and p ,
0.01) reduction of the number of transformed B cells after
addition of allogeneic polyI:C DCs or DC1s, respectively
(Figure 2D and 2E). These data suggest that tonsilar NK cells
are able to restrict B cell transformation by EBV after
stimulation by polyI:C DCs and DC1s.
NK cells are present in tonsils at lower frequencies than in
peripheral blood (0.3% compared to 10%), corresponding to
only 3000 NK cells in a tonsilar B cell transformation assay
with 6310
5 B cells (NK to B cell ratio of 1:200). However, the
ratio between CD56
dimCD16
þand CD56
brightCD16
 NK cells is
almost reversed between these organs with 75% of all NK cells
being CD56
brightCD16
  in tonsils and only 5% being
CD56
brightCD16
  in peripheral blood [27]. To compare
directly the abilities of NK cells from blood and tonsils to
restrict B cell transformation, we tested different ratios of
blood NK cells to B cells. In addition to an intermediate ratio
(NK:B ¼ 1:1), we mimicked NK cell to B cell ratios found in
tonsils (NK:B ¼ 1:200; 60% B and 0.3% NK cells). We also
added sufﬁcient peripheral blood NK cells to mimic the
CD56
brightCD16
 NK cell to B cell ratio found in tonsil (NK:B¼
1:13.3; CD56
brightCD16
  NK cells are 15fold enriched in bulk
tonsilar NK cells compared to blood NK cells: 75% in tonsil
and5% inblood). Already at a ratio of 1:1 we could only detect
a limited 6% reduction of B cell transformation compared to
controls (Figure 3A and 3B). These ﬁndings indicate that
tonsilar NK cells are 1000-fold more efﬁcient in controlling B
cell transformation than peripheral blood NK cells.
CD56
brightCD16
  NK Cells Restrict EBV-Induced B Cell
Transformation Most Efficiently
To study which subset of NK cells limits B cell trans-
formation, we sorted NK cell subsets from blood and
activated them with DC1s. While sorted CD56
dimCD16
þ NK
cells did not mediate restriction of B cell transformation
(NK:B ¼ 4.5:1), low numbers of CD56
brightCD16
  NK cells
(NK:B ¼ 1:2) were found to inhibit B cell transformation
(34%) similar to 10-fold higher numbers of bulk NK cells
(Figure 3A and 3B). Next, we sorted NK cell subsets from
tonsils and observed that again CD56
brightCD16
  NK cells but
not CD56
dimCD16
þ NK cells were efﬁciently limiting B cell
transformation after activation by DC1 (Figure 3C and 3D).
At 10-fold lower numbers, tonsilar CD56
brightCD16
  cells
inhibited B cell transformation more (48.3% vs. 34%) than
their counterparts in blood. Since CD56
brightCD16
  NK cells
are 15-fold enriched in tonsils compared to blood, NK cell
mediated restriction is achieved with at least 150-fold lower
bulk NK cell numbers in this organ. Further increasing the
number of tonsilar NK cells 5-fold (NK:B ¼ 1:40) led to
restriction of B cell transformation by 69.7% (Figure 3C and
3D). Moreover, high numbers of splenic CD56
brightCD16
  NK
cells (NK:B¼5:1), a mixture of blood and secondary lymphoid
organ NK cells, when activated with matured autologous
myeloid CD11c
high DCs isolated from spleen, restricted B cell
transformation by 67% (Figure 3E and 3F). Since we observed
that at lower ratios of blood NK cells to B cells, even puriﬁed
CD56
brightCD16
  peripheral blood NK cells were unable to
limit B cell transformation after activation by polyI:C DCs
and DC1s, whereas tonsilar NK cells were still able to restrict
EBV-induced B cell transformation, we concluded that
tonsilar CD56
brightCD16
  NK cells are functionally different
Table 1. Secretion of IL-12, IL-15, and IL-18 by DCs
DC Type Maturation IL-12 IL-15
a IL-18
a
Monocyte-derived
DCs (n ¼ 6)
None ,16.25
b 12 6 11 40 6 32
pc 29 6 25 78 6 40 55 6 23
polyI:C 2445 6 985 159 6 68 44 6 11
DC1 4123 6 1098 289 6 84 50 6 19
LPS 69 6 40 n.d. n.d.
dsRNA 85 6 35 n.d. n.d.
aSamples were 10-fold concentrated.
bValues indicate concentration of cytokine in pg/ml þ/  standard deviation.
n.d., not determined.
doi:10.1371/journal.ppat.0040027.t001
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NK Cells Limit EBV Infectionfrom their counterparts in peripheral blood, and inhibit
EBV-induced B cell transformation more efﬁciently.
Tonsilar and Lymph Node NK Cells Produce Higher Levels
of the Anti-viral Cytokine IFN-c than Peripheral Blood NK
Cells
Human NK cells from secondary lymphoid organs such as
tonsils produce IFN-c rapidly upon activation and this
antiviral cytokine contributes directly to control early
infection in murine models of herpes virus infection [33].
When we compared the production of IFN-c upon NK cell/
DC coculture, we observed that NK cells from tonsil and
lymph node produced signiﬁcantly more IFN-c than their
equivalents from blood or spleen (Figure 4A). Comparing
CD56
brightCD16
  NK cells, tonsilar and lymph node cells
produced 5-fold more IFN-c than peripheral blood cells,
which amounted to a 50-fold difference when bulk NK cell
cultures were analyzed due to the enrichment of
CD56
brightCD16
  NK cells in these organs. It had recently
been reported that IL-18 exposed blood NK cells develop into
a CD56
brightCD83
þCCR7
þ NK cell subset with superior IFN-c
production [35]. In order to test if an enrichment of this NK
cell subset could account for the superior ability of tonsilar
Figure 2. NK Cells from Blood and Tonsil Activated by PolyI:C-matured DCs Limit EBV-mediated B Cell Transformation
(A) B cells were infected with EBV and cultured for 12 d alone, with DCs or NK cells and with DCs plus NK cells. The indicated percentage of B cell
transformation was evaluated by determining the percentage of transformed CD19
þCD23
þB cells within gated CD19
þCD21
þ B cells.
(B and C) Total numbers of transformed B cells were determined from live cell numbers and the percentage of transformed CD19
þCD23
þB cells in the
different cultures. Total transformed B cell numbers for one representative experiment (B), and differences in total transformed B cell numbers for all
experiments (percentage restriction of B cell transformation) (C), were analyzed with or without peripheral blood NK cell addition for the indicatedD C
maturation conditions. Data represent results from eight independent experiments (mean 6 standard error of the mean).
(D and E) Mononuclear cells from tonsils were depleted of CD3
þ T cells or CD3
þ T and CD56
þ NK cells. Total numbers of transformed B cells were
determined from live cell numbers and the percentage of transformed CD19
þCD23
þ B cells in the different cultures. Total transformed B cell numbers
for one representative experiment (D), and differences in total transformed B cell numbers for all experiments (percentage restriction of B cell
transformation) (E), were analyzed with and without tonsilar NK cells for the indicated DC maturation conditions. Data represent results from six
independent experiments (mean 6 standard error of the mean).
doi:10.1371/journal.ppat.0040027.g002
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NK Cells Limit EBV InfectionNK cells to produce IFN-c, we analyzed CD83 and CCR7
expression on tonsilar NK cells (Figure S4). Conﬁrming our
previously published data [28], we found no CCR7 expression
on tonsilar NK cells, and only a minor population expressed
CD83. Therefore, an enrichment of CD83
þCCR7
þ NK cells
with superior IFN-c production does not explain why NK
cells from secondary lymphoid organs produce more IFN-c
than their peripheral blood counterparts.
IFN-c Levels Correlate with NK Cell Induced Restriction of
B Cell Transformation by EBV
Higher IFN-c secretion by tonsilar NK cells was also
apparent when we then quantiﬁed the levels of IFN-c in the
culture supernatants of the B cell transformation assay after
12 days. We detected high levels in cocultures of NK cells
from blood with polyI:C DCs (960 pg/ml; data not shown) or
DC1s (1560 pg/ml; Figure 4C), but only with the highest
numbers of NK cells (NK:B¼5:1). However, IFN-c levels were
even higher in B cell transformation cultures with bulk
tonsilar NK cells and polyI:C DCs (1140 pg/ml) or DC1s (2500
pg/ml), and this IFN-c secretion was NK cell dependent
(Figure 4B). Furthermore, we detected similar levels of IFN-c
also in cultures with sorted CD56
brightCD16
  NK cells from
blood, tonsil and spleen (Figure 4C and 4D and data not
shown), reaching up to 4000pg/ml IFN-c concentrations with
puriﬁed tonsilar CD56
brightCD16
  NK cells. Therefore, only
DC/NK cell co-cultures with polyI:C matured DCs and either
high peripheral blood or low tonsilar NK cell numbers
produce IFN-c concentrations above 1000 pg/ml, and only
these high IFN-c levels correlate with control of EBV-
transformed B cells.
Restriction of EBV-Induced B Cell Transformation by NK
Cells Relies on IFN-c
In order to estimate the contribution of NK cell-produced
IFN-c on control of EBV-infected B cells, we added
Figure 3. CD56
brightCD16
  Cells from Blood, Tonsil, and Spleen Limit EBV-mediated B Cell Transformation after Activation by DCs
(A and B) B cells were infected with EBV and cultured for 12 d with peripheral blood NK cells and DC1s at the indicated NK cell to B cell ratios. Total NK
cells were compared to sorted CD56
brightCD16
  and CD56
dimCD16
þ NK cells in their ability to limit EBV-mediated B cell transformation. Total
transformed B cell numbers for one representative experiment (A) and restriction of B cell transformation for all experiments (B) were compared after
addition of unseparated bulk NK cells (total NK), CD56
dimCD16
þNK cells (90% of the bulk NK cell number) or CD56
brightCD16
 NK cells (10% of the bulk
NK cell number, to respect the NK subset distribution in peripheral blood) (*, p , 0.01).
(C and D) Tonsilar B cells were infected with EBV and cultured for 12 d alone or with autologous tonsilar NK cell subsets at 2 ratios (NK, 5,000 and 5-fold
NK, 25,000) in the absence or presence of allogeneic iDCs or DC1s (*, p , 0.01). Total transformed B cell numbers for one representative experiment (C),
and restriction of B cell transformation for all experiments are shown (D).
(E and F) Splenic B cells were infected with EBV and cultured for 12 d alone or with autologous splenic NK cell subsets in the absence or presence of
autologous splenic DCs matured with polyI:C, TNF-a, IL-1b, IFN-a and IFN-c (*, p , 0.01). Total transformed B cell numbers for one representative
experiment (E), and restriction of B cell transformation for all experiments are shown (F). Data in (A–F) represent results from three independent
experiments (mean 6 standard error of the mean).
doi:10.1371/journal.ppat.0040027.g003
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NK Cells Limit EBV Infectionrecombinant IFN-c to puriﬁed and EBV-infected B cells from
blood, spleen and tonsil. We detected fewer transformed B
cells in cultures with high levels of IFN-c (from 1000 to 10000
pg/ml) compared to controls with low levels (from 10 pg/ml to
200 pg/ml) of IFN-c or without IFN-c (Figure 4E). Indeed,
42% restriction of B cell transformation (p , 0.02) was
observed in tonsilar B cell cultures with 5000 pg/ml IFN-c,a n
IFN-c concentration that was produced by tonsilar NK cells
upon culture with polyI:C DCs and DC1s, and similar to
measured IFN-c levels in tonsil cell cultures (Figure 4A and
4D). However, IFN-c mediated restriction of B cell trans-
formation by EBV only limits, but does not eradicate EBV
infection, since even with IFN-c concentrations exceeding
10,000 pg/ml, we never observed more than 80% inhibition of
B cell transformation by EBV (data not shown). Finally, DC
activated NK cell were still able to mediate restriction when
separated by transwell from EBV-infected B cells, and we
could block inhibition of B cell transformation by over 60%
using blocking antibodies against IFN-c (Figure 4F). There-
fore, IFN-c contributes to NK cell-mediated restriction of
EBV-induced B cell transformation.
Myeloid DCs Sense EBV Directly and Elicit IFN-c Secretion
by NK Cells to Levels Protective against EBV-Induced B
Cell Transformation
In order to extend our ﬁndings from monocyte-derived DCs
to human blood DCs and from polyI:C to maturation by EBV,
we exposed sorted human CD11c
þ myeloid DCs to EBV
particles directly (DC:EBV MOI¼1:1). We observed 189 6 20
pg/ml IL-12 secretion and upregulation of the maturation
Figure 4. IFN-c Secreted by NK Cells Restricts EBV-mediated B Cell Transformation
(A) Sorted NK cell subsets from blood, spleen, tonsil, and lymph node were cultured alone or with DC1s, and IFN-c levels were quantified by ELISA after
20 h.
(B) IFN-c secreted by tonsilar NK cells after activation by differently matured DCs was detected in supernatants of B cell transformation assays by ELISA.
(Tonsil–T, tonsilar cultures depleted of T cells; Tonsil–T-NK, tonsilar cultures depleted of T and NK cells.)
(C) IFN-c secreted by peripheral blood NK cells and NK cell subsets was detected in supernatants of B cell transformation assays by ELISA.
(D) IFN-c secreted by purified tonsilar NK cell subsets was detected in supernatants of B cell transformation assays by ELISA.
(E) Peripheral blood B cells were infected with EBV and increasing concentrations of IFN-c were added. Restriction of B cell transformation was analyzed
after 12 d by comparing numbers of transformed B cells with and without IFN-c.
(F) Blocking antibodies against IFN-c were added to B cell transformation assays with B cells, NK cells, and DC1s from peripheral blood. Where indicated,
NK cells were separated from B cells and DCs by transwell membranes. Results from at least three independent experiments were summarized (mean 6
standard deviation) (*, p , 0.03).
doi:10.1371/journal.ppat.0040027.g004
PLoS Pathogens | www.plospathogens.org February 2008 | Volume 4 | Issue 2 | e27 0007
NK Cells Limit EBV Infectionmarker CD83 upon coculture of myeloid DCs with EBV
(Figure 5A and 5B). Both infectious and heat-inactivated EBV
elicited this DC maturation (Figure 5A). DC maturation by
EBV was not due to endotoxin contamination of the EBV virus
preparations, since we detected less than in 0.1 ng endotoxin
in 1 3 10
5 EBV RIU, a concentration insufﬁcient for human
DC maturation (Figure 5A). Furthermore polymyxin B, which
inhibits TLR4 stimulation by LPS [36], had no effect on EBV-
mediated DC maturation, but signiﬁcantly inhibited DC
maturation by LPS (Figure 5A). While EBV induced IL-12
levels were lower than IL-12 concentrations in response to
polyI:C and to high levels of LPS (1286 6 188 pg/ml and 763 6
87 pg/ml, respectively; Figure 5A), EBV-matured DCs stimu-
lated puriﬁed autologous NK cells to secrete IFN-c in excess of
4000 pg/ml via IL-12 (Figure 5C). These IFN-c concentrations
are high enough to inhibit B cell transformation by EBV in
vitro (Figure 4E). These data suggest that human myeloid DCs
can be matured by EBV and then activate NK cells to produce
protective amounts of IFN-c.
IFN-c Regulates B Cell Transforming EBV Latency
In order to investigate how IFN-c restricts B cell trans-
formation, we infected B cells with EBV and compared total
cell numbers, proliferation and expression of EBV-encoded
genes between untreated and IFN-c-treated cells. We started
observing signiﬁcant differences in cell numbers from day 4
(Figure 6A). This coincided with beginning EBV-infected B
cell proliferation, which was delayed when cells were treated
with IFN-c (Figure 6B). Comparing expression of different
EBV-encoded genes showed that EBER1, EBNA2, and EBNA1
were similarly up-regulated in untreated and IFN-c-treated
EBV-infected B cells. In contrast, we observed a delayed up-
regulation of LMP1 in IFN-c-treated cultures (Figure 6C and
data not shown). Quantitative RT-PCR demonstrated that
expression of LMP1 was reduced by 28% and 49% at days 3
and 5 post infection, while at later stages similar LMP1 levels
were observed with and without IFN-c addition, when
normalized to GAPDH (Figure 6D). Notably, recombinant
IFN-c did not mediate restriction of B cell transformation
when added later than 96h after EBV infection (Figure 6E),
and also did not inhibit growth of established EBV-trans-
formed B cell lines (data not shown). We did not observe any
effect of IFN-c on B cell viability as measured by counting live
cells up to day 6 post-infection, and levels of the EBV receptor
CD21 were not affected by IFN-c treatment (data not shown).
Therefore, we suggest that DC activated NK cells limit B cell
transformation by EBV via regulation of EBV latent infection,
at least in part via delaying LMP1 expression via IFN-c.
Discussion
NK cells and DCs are central ﬁgures in the innate immune
response, and have been shown to interact in early phases of
murine herpes virus infections [18,19,34,37]. In contrast to
the mouse, humans possess the CD56
brightCD16
 subset of NK
cells, which rapidly secretes high IFN-c levels and strongly
proliferates upon activation by DCs [29]. These NK cells are
enriched in secondary lymphoid organs like tonsils and
lymph nodes, and are therefore strategically positioned to
rapidly respond to pathogens at these sites [26–28]. Such a
pathogen is the human tumor virus EBV, which enters the
human body through the tonsils after transmission via saliva
exchange. Within tonsils of healthy virus carriers, the
proliferation program, which is also observed in in vitro
EBV-infected B cells, was found in naı ¨ve B cells, which travel
through the perifollicular T cell zone and follicular mantle
zone to encounter antigen [38,39]. These areas were also
described to harbor or are close to DC/NK cell interactions
[30,40,41]. Our data suggest that at these sites, human DCs can
activate preferentially CD56
brightCD16
  NK cells, which then
become able to limit EBV-mediated B cell transformation,
mainly by secretion of IFN-c, and regulate the proliferation
Figure 5. Myeloid DCs Can Sense EBV and Subsequently Activate NK
Cells via IL-12
(A) CD11c
þ myeloid DCs (1 3 10
5) were purified to 99.8% purity by flow
cytometric sorting and exposed to polyI:C (25 lg/ml), EBV (MOI of 1, 53
10
5 RIU/ml), and LPS in the absence and presence of polymyxin B (25 lg/
ml), an inhibitor of LPS-mediated TLR4 activation. IL-12p70 was detected
by ELISA 24 h later.
(B) Purified DCs were exposed to polyI:C (25 lg/ml) or EBV (MOI of 1, 53
10
5 RIU/m), and upregulation of the DC maturation marker CD83 was
detected by flow cytometry 24 h later.
(C) Flow-sorted CD11c
þ DCs and peripheral blood NK cells were cultured
together or separately in the presence of polyI:C (25 lg/ml), or EBV (MOI
of 1, 5 3 10
5 RIU/ml). IFN-c was detected by ELISA 24 h later. Where
indicated, IL-12 was blocked in selected experiments with a specific
antibody (n.d., not determined). Data represent results from at least
three independent experiments performed in duplicates.
doi:10.1371/journal.ppat.0040027.g005
PLoS Pathogens | www.plospathogens.org February 2008 | Volume 4 | Issue 2 | e27 0008
NK Cells Limit EBV Infectionprogram of EBV latency via this cytokine. Restriction of EBV-
induced B cell transformation by NK cells probably curtails
EBV infection until it can be efﬁciently immune controlled by
the adaptive immune system. These results suggest for the
ﬁrst time an important effector function for tonsilar NK cells
early in the primary immune response against human
persistent and oncogenic EBV.
iDCs patrol the periphery and act as sentinels for the
immune system [42]. Upon direct infection by a pathogen or
uptake of pathogen-containing material in conjunction with
a maturation stimulus they migrate to secondary lymphoid
organs carrying information both in the form of a particular
maturation pattern and pathogen constituents. DC matura-
tion changes drastically the properties of DCs converting
them into potent activators of both the innate and adaptive
immune system. One group of DC receptors that detect
pathogenic determinants and trigger the activating functions
of DCs are TLRs [43]. In murine herpes virus infections, it has
been shown that different pathways synergize for the
activation of immune responses against these pathogens.
TLR9-deﬁcient mice as well as TLR3- and TLR2-deﬁcient
mice have increased MCMV titers, suggesting that the
immune system uses complementing recognition systems in
herpes virus infection [18,20,44]. Similarly, EBV might
activate human DCs by means of several pathways. In
addition to TLR9-activating CpG-motifs, by which EBV
activates human plasmacytoid DCs [45], the EBV genome
supports convergent transcription, which occurs also in other
DNA viruses such as herpes simplex virus-1 (HSV-1) [46,47].
The resulting virally encoded dsRNAs have been isolated
from HSV-1-infected cells [48]. Indeed, dsRNA from the
convergently transcribed LMP1 and LMP2A antigens of EBV
was able to stimulate IL-12 secretion. The measured IL-12
amounts were similar to levels secreted by CD11c
þ DCs after
exposure to EBV particles (Figure 5A; Table 1). Consequently,
we suggest that myeloid DCs can detect EBV either directly,
Figure 6. IFN-c Impairs Transformation of B Cells by EBV
(A) Cell numbers were compared at different time points between control and IFN-c-treated B cells with and without EBV infection.
(B) CFSE-labeled B cellswere infectedwith EBV,andproliferationwas comparedbetweencontrolsandIFN-c-treatedsamples atthe indicatedtimepoints.
(C) Expression of EBV-encoded genes was quantified by RT-PCR at different time points and compared between controls and IFN-c-treated cells. M, 100
bp ladder (D) Expression of the oncogene LMP-1 was quantified by real time-PCR and normalized to GAPDH expression.
(E) Peripheral blood B cells were infected with EBV, and 10,000 pg/ml IFN-c was added at the indicated time points. Restriction of B cell transformation
was analyzed after 12 d by comparing numbers of transformed B cells with and without IFN-c. Results represent data from at least three independent
experiments.
doi:10.1371/journal.ppat.0040027.g006
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NK Cells Limit EBV Infectionor indirectly through EBV-derived dsRNA as TLR3 and mda-
5 agonists during primary infection and subsequently initiate
the immune response by activating NK cells and priming of T
cells [49,50]. Along these lines, DC-activated NK cells might
have limited B cell transformation by EBV in a previous study
from our lab, but complete regression of transformed B cells
was only achieved after DC dependent priming of EBV-
speciﬁc T cell responses and was also observed with puriﬁed
CD4
þ and CD8
þ T cells [51].
In line with previous studies, we ﬁnd that phenotypical
markers such as MHC class II and costimulatory molecules
are equally upregulated with various DC maturation stimuli,
while cytokine secretion proﬁles varied dramatically between
different DC maturation conditions. In particular, IL-12p70,
a potent stimulator of NK cells and Th1 responses, was
produced at higher levels by DCs exposed to EBV, or matured
with EBV-derived dsRNA or with maturation cocktails
containing the dsRNA analog polyI:C, compared to immature
DCs or DCs matured with proinﬂammatory cytokines or LPS.
Nonetheless, even low levels of IL-12 secreted by LPS-
matured DCs through directed secretion into the synapse
between NK cells and DCs have been shown to activate NK
cells [52]. Hence, our data suggest that myeloid DCs stimulate
NK cell responses during primary EBV infection at least in
part via IL-12.
Two main functional subsets of NK cells have been
described in humans, while counterparts for these NK cell
populations have not been identiﬁed in the mouse so far [25].
The CD56
dimCD16
þ subset is mainly responsible for natural
cytotoxicity and antibody-dependent cell mediated cytotox-
icity (ADCC), while the CD56
brightCD16
  subset has been
characterized by its unique capacity to produce high amounts
of immunoregulatory cytokines, such as TNF, IFN-c and GM-
CSF, upon activation [25]. IFN-c production by
CD56
brightCD16
  NK cells, as well as NK cell proliferation
are rapidly induced by DCs [30]. In addition, DCs also
augment cytotoxicity of this subset after prolonged activation
[53]. Several studies indicate a role for NK cells in the control
of EBV infection and in particular in early primary immune
responses [8–10,54]. However, all in vitro studies up to now
have used blood NK cells activated by IL-2, which is, at least in
humans, mostly secreted by activated T cells and therefore
presumably not present during innate immune responses.
Hence, we focused on NK activation by DCs as a physiological
NK cell stimulus present during the early immune response
to primary virus infections. Furthermore, previous studies on
the role of NK cells during EBV infection mainly emphasized
cytotoxicity, but not IFN-c secretion of NK cells, although
lymph node- and tonsil-resident NK cells primarily release
cytokines after activation [26,28,30]. Suggesting a prominent
role for NK cell-derived cytokines early during EBV infection,
earlier studies have found that recombinant IFN-c is
protective for several days during initial B cell transforma-
tion by EBV, whereas in contrast, type I interferons inhibit
transformation only during the ﬁrst hours after infection
[55]. Moreover, EBV-speciﬁc CD4
þ and CD8
þ T cells have
been reported to mediate regression of EBV-transformed B
cells despite low to undetectable cytolytic activity [56,57]. Our
data support the hypothesis that tonsilar NK cells restrict
efﬁciently EBV-induced B cell transformation via their
superior ability to produce IFN-c upon DC activation.
Although IL-12 and IFN-a secreted by polyI:C DCs and
DC1s upregulate cytotoxicity of NK cells (Figure S3),
autologous EBV-transformed B cells are not efﬁciently killed
by activated NK cells due to their high MHC class I expression
(data not shown and [12]). Instead, the results of this study
support a prominent role for IFN-c in the innate immune
response to EBV by NK cells. First, addition of recombinant
IFN-c to the B cell transformation assay decreased the
number of transformed B cells. Second, IFN-c levels,
sufﬁcient to restrict EBV-induced B cell transformation,
were found in our cocultures of EBV-infected B cells with
DCs and NK cells. Finally, blocking of IFN-c in B cell
transformation assays with NK cells signiﬁcantly decreased
the protective effect of NK cells. Hence, we conclude that this
cytokine signiﬁcantly contributes to innate resistance against
primary EBV infection. In addition to its direct antiviral
activity, IFN-c secreted by DC-activated NK cells might also
shape the EBV-speciﬁc adaptive immune response favoring a
Th1-polarization which is observed in EBV-positive individ-
uals [58–61]. Therefore, contrary to the original paradigm
that NK cells respond primarily with cytotoxicity without
prior activation, which gave this lymphocyte subset its name,
we demonstrate that their main function against a relevant
human pathogen consists of cytokine secretion after activa-
tion by DCs.
EBV transforms B cells by the coordinate expression of
EBV latency genes that provide signals for B cell survival and
proliferation. Of the eight latent EBV antigens, LMP1 has
been suggested to be the main oncogene of the virus, causing
epithelial cell transformation in vitro and B cell trans-
formation in vivo [62–64]. Therefore, IFN-c induced down-
regulation of LMP1 transcription could be one mechanism by
which DC-activated NK cells limit EBV-induced B cell
expansion. The fairly late transcription of LMP1, compared
to other EBV latent antigens, during the establishment of
EBV latency could also explain why IFN-c can restrict B cell
transformation by EBV during the ﬁrst days of primary EBV
infection, while others and we found that IFN-c was not able
to inhibit proliferation of fully EBV-transformed lympho-
blastoid cell lines (LCLs) ([55] and data not shown). Similarly,
IFN-c secretion by NK cells was shown to limit MCMV
infection during the ﬁrst week of infection, and reduced
immediate early or late MCMV gene transcription, depending
on the infected cell type [33,65]. Therefore, tonsilar NK cells
might limit latent EBV infection by IFN-c mediated down-
regulation of LMP1 until adaptive T cell immune responses
can eliminate fully EBV-transformed B cells.
In summary, we suggest that myeloid DCs stimulate NK
cells during EBV infection primarily via their ability to
secrete IL-12. Activated NK cells are then able to mediate
restriction of EBV-mediated B cell transformation. Tonsilar
NK cells, which, like lymph node NK cells, produce higher
levels of IFN-c than their peripheral blood counterparts after
activation by DCs, are superior in inhibiting EBV-induced B
cell transformation in vitro by down-regulating important
components in the proliferation program of EBV latency.
These results suggest a novel and important effector function
for tonsilar CD56
brightCD16
  NK cells upon DC activation in
the primary immune response against EBV. Beyond EBV
infection, our data suggest that humans have a strategically
well-positioned population of NK cells that directly combats
pathogen entry at mucosal sites and might restrict pathogens
until they can be cleared or controlled by adaptive immunity.
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Antibodies. The following directly-labeled monoclonal antibodies
were used for ﬂow cytometry: anti-CD3 (clone SK7), anti-CD11c (B-
ly6), anti-CD19 (HIB19), anti-CD21 (B-ly4), anti-CD23 (M-L233), anti-
CD56 (B-159), anti-CD80 (L307.4), anti-CD86 (IT2.2), anti-HLA-DR
(TU36), anti-IFN-c (B27, all BD Biosciences), anti-CD16 (3G8, Caltag),
anti-CD25 (PC61 5.3), anti-CD83 (HB15a, both Beckman Coulter),
and anti-IL-15 (34599, R&D Systems). Cells labeled with goat-
polyclonal anti-IL-15Ra (R&D Systems) were stained with Alexa-
Fluor-488 rabbit-anti-goat-IgG (Molecular Probes). The following
monoclonal antibodies were used for antibody-mediated blocking:
anti-IL-12 (clone 24910), anti-IL15 (34593, both R&D Systems), and
anti-IL-18 (125–2H, MBL International). IgG1 (MOPC-21, BioLegend)
was used as control.
Tonsils, lymph nodes, and spleens. All tonsils, lymph nodes and
spleens were obtained as part of Institutional Review Board-approved
protocols. Tonsils were collected immediately after surgery from
patients undergoing tonsilectomy for chronic inﬂammation. Tonsils
were not acutely inﬂamed at the time of removal. Spleens and lymph
nodes were procured by the regional Organ Procurement Organ-
ization from brain-dead donors after obtaining informed consent
from appropriate individuals. Soon after their removal, tissues were
mechanically dissociated to obtain single cell suspensions and were
then ﬁltered through a 75-lm nylon cell strainer to exclude
undissociated fragments. Debris and dead cells were eliminated using
Ficoll/Hypaque (Amersham Pharmacia) discontinuous gradient cen-
trifugation. Single cell suspensions were then extensively washed and
cryopreserved.
Preparation of DCs. PBMCs were isolated from leukocyte concen-
trates (New York Blood Center) by density-gradient centrifugation on
Ficoll/Hypaque. CD14
þ cells were isolated from PBMCs by positive
magnetic cell separation (MACS, Miltenyi Biotec) and cultured for 5
days in RPMI1640 þ 1% single donor plasma þ IL-4 and GM-CSF
according to standard protocols [30]. The CD14
 cells were frozen for
later isolation of B cells and NK cells. Splenic DCs were isolated as
previously described by ﬂow cytometric sorting using a BD
FACSVantage SE cell sorter [30]. To isolate CD11c
þ cells from blood,
PBMCs were overlayed with an Optiprep gradient (1.080 to 1.049)
and centrifuged for 30 min at 7003g. Low-density fractions were
collected and CD11c
þ DC were further enriched by depletion of
CD14
þ, CD3
þ, CD8
þ, and CD19
þ cells by MACS. CD11c
þ DCs were
puriﬁed by ﬂow cytometric sorting using a BD FACS Aria cell sorter
by isolating lin- (CD3, CD14, CD19, and CD56), HLA-DR
þ, and
CD11c
þ cells. Purify after sorting was regularly higher than 99.5%.
DCs were matured for 2d in medium with IL-4, GM-CSF, and i) 10 ng/
ml IL-1b,1 , 0 0 0u n i t s / m lI L - 6 ,1 0n g / m lT N F - a,a n d1lg/ml
prostaglandin E2 (cyt DC), ii) 25 lg/ml polyinosine-polycytidylic acid
(polyI:C, Invivogen) (polyI:C DC), iii) 25 ng/ml IL-1b, 50 ng/ml TNF-a,
3,000 IU/ml IFN-a, 500 pg/ml IFN-c, and 25 lg/ml polyI:C (DC1), iv)
250 ng/ml LPS (Sigma) (lps DC). CD11c
þ DCs were exposed to AGS-
cell derived EBV at an MOI of 1. Maturation of DCs was monitored by
ﬂow cytometry using anti-CD25, anti-CD80, anti-CD83, anti-CD86,
and anti-HLA-DR. Secretion of cytokines was quantiﬁed using IL-
12p70 ELISA, IL-15 ELISA (both R&D Systems) and IL-18 ELISA
(Bender Medsystems).
Isolation of B cells and NK cells. Frozen CD14
  PBMCs were
thawed, washed and B cells were isolated by positive selection using
CD19
  Microbeads (Miltenyi Biotec). NK cells were isolated from
either CD19
  or CD14
  fractions by negative selection using the NK
cell Isolation Kit II (Miltenyi Biotec) according to the manufacturer’s
instructions. The purity of the isolated B cells and NK cells was higher
than 90% and contained less than 5% contaminating T cells as
determined by ﬂow cytometry. For other experiments, B cells, NK
cells, and NK cell subsets were isolated by ﬂow cytometric sorting
using a BD FACSVantage SE cell sorter.
Preparation of EBV. The EBV
þ marmorset cell line B95–8 was
seededat2310
5cells/mlandculturedfor12dinRPMI1640þ10%FCS
þ gentamycin without refeeding. Virus-containing supernatant was
centrifugedat2000rpmfor10minandpassedthrougha0.45lmﬁlter.
EBV
þAGScellswereusedtoproduceEBVaspreviouslydescribed,and
viruswasfurtherconcentratedandpuriﬁedbyultracentrifugation[66].
AGS-derived EBV preparations contained less than 0.1 EU/ml
endotoxins as measured by LAL test (Cambrex Corporation).
Generation of EBV-derived dsRNA. A 1.3 kB fragment spanning
the coding region of LMP1 in one direction and part of the ﬁrst
intron of LMP2A in the other direction was cloned into pGEM
(Promega) between the T7 and SP6 promoter. ssRNA was generated
using linearized plasmid and the Riboprobe Combination System
SP6/T7 (Promega). After veriﬁcation of integrity of RNA by gel
electrophoresis, ssRNA was puriﬁed using RNeasy Kit (Qiagen) and
quantiﬁed by Nanodrop. Finally, equal amounts were annealed in
siRNA buffer (Dharmacon) to generate dsRNA and successful
annealing was conﬁrmed by gel electrophoresis.
Proliferation assay. Isolated NK cells were labeled with 1 lM CFSE
in PBS plus 0.1% BSA for 10 min at 378C. After washing twice with
RPMI1640þ5% human serumþgentamycin, NK cells (2.5310
5 cells
in 96 well plate) were cultured with 500 IU/ml IL-2 or autologous DCs
at a ratio of 5:1 for 6 days at 378C in RPMI1640þ5% human serumþ
gentamycin. In selected experiments, isotype control antibody (5 lg/
ml) or blocking antibodies against IL-12, IL-15 (5 lg/ml each), and IL-
18 (1 lg/ml) were added to the cultures at the beginning and on day 3
of culture. Where indicated, DCs (bottom) were separated from NK
cells (top) by 0.4 lm pore membranes (Corning). CFSE ﬂuorescence
and CD16 staining was evaluated on CD3
 CD56
þ cells by ﬂow
cytometry. Where indicated, B cells were CFSE labeled as described
above and proliferation of CD19
þCD20
þ cells was evaluated with and
without 10,000 pg/ml IFN-c addition after infection with EBV as CFSE
dilution by ﬂow cytometry. Live cell numbers were determined by
trypan blue exclusion.
IFN-c assay. For intracellular staining of IFN-c, isolated NK cells
from blood (2.5 3 10
5 cells in 96 well plate) were incubated with 500
IU/ml IL-2 or autologous DCs at a ratio of 1:2 at 378C in RPMI1640þ
5% human serum þ gentamycin. In selected experiments, isotype
control antibody (5 lg/ml) or blocking antibodies against IL-12, IL-15
(5 lg/ml each), and IL-18 (1 lg/ml) were added. Brefeldin-A was added
after 6 h of coculture and additional 6 h later cells were harvested and
stained with anti-CD3, anti-CD56 and anti-CD16. After ﬁxing the
cells with 2% paraformaldehyde, they were permeabilized and
stained with anti-IFN-c. In other experiments, DCs (bottom) were
separated from NK cells (top) by 0.4 lm pore membranes and IFN-c
production was compared to NK-DC cocultures without separation
after 20h using an IFN-c ELISA (Mabtech). To directly compare IFN-c
production, sorted NK cell subsets from blood, spleen, tonsil and
lymph node (1 3 10
4 cells CD56
brightCD16
 ,13 10
5 CD56
þCD16
þ)
were then cultured with allogeneic or autologous DCs at a ratio of
1:10 or 1:1, respectively. After 20 h IFN-c levels were determined
using ELISA.
B cell transformation assay with peripheral blood, splenic, and
tonsilar mononuclear cells. Isolated B cells (1 3 10
5 cells in 48 well
plate) were cultured in RPMI1640þ5% human serumþgentamycin,
infected with EBV and isolated NK cells were added at indicated
numbers. In experiments including DCs, they were added at B cell to
DC ratios of 1:1. In other experiments, B cells and DCs (bottom) were
separated from NK cells (top) by 0.4 lm porous membranes. After 12
d, numbers of transformed B cells were quantiﬁed by counting live
cells via trypan blue exclusion and determining the ratio of
CD19
þCD21
þCD23
þ cells to total live cells by ﬂow cytometry.
Restriction of B cell transformation was calculated by comparing
numbers of transformed B cells between respective samples with and
without NK cells; % Restriction of B cell transformation ¼ (1   total
transformed B cell number of sample with NK cells/total transformed
B cell number of sample without NK cells) 3 100.
B cell transformation assay with bulk tonsilar mononuclear cells.
Cryopreserved tonsilar mononuclear cells were thawed, washed, and
then stained with anti-CD3 and anti-CD56. Cells were then depleted
(i) of CD3
þ cells (Tonsil -T) or (ii) of CD3
þ and CD56
þ cells (Tonsil -
NK-T) by ﬂow cytometric sorting using a BD FACSVantage SE cell
sorter. The number of sorted cells per condition was adjusted
according to the ratio between sorted cells and input cell numbers
(1 3 10
6 cells in 48 well plate). Then, the cells were infected with
EBV and, where indicated, DCs were added at ratio of total cell to
DC of 10:1. After 12 d, numbers of transformed B cells were
quantiﬁed by counting live cells via trypan blue exclusion and
determining the ratio of CD19
þCD21
þCD23
þ cells to total live cells
by ﬂow cytometry. Restriction of B cell transformation was
calculated by comparing numbers of transformed B cells between
respective samples with and without NK cells; % Restriction of B
cell transformation ¼ (1   total transformed B cell number of
sample with NK cells/total transformed B cell number of sample
without NK cells) 3 100.
Quantiﬁcation of EBV mRNAs. RNA was isolated from non-treated
and IFN-c-treated B cells infected with EBV at indicated time point
using the RNeasy Kit (Qiagen) according to the manufacturer’s
instructions. 10 ng of total RNA were used for semi-quantitative RT-
PCR using the OneStep RT-PCR-Kit (Qiagen) and gene-speciﬁc
primers using the following program: 508C (30 min), 958C (15 min),
followed by 35 cycles of 958C (30 sec), 558C (30 sec), and 728C (30 sec).
Primers sequences were as follows: Actin 59-CAAGAGATGGC-
CACGGCTGCT, Actin 39-TCCTTCTGCATCCTGTCGGCA, EBNA1
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GTACCT, EBNA2 59-CATAGAAGAAGAAGAGGATGAAGA, EBNA2
39-GTAGGGATTCGAGGGAATTACTGA, EBER1 59-AAAACATGCG-
GACCACCAGC, EBER1 39-AGGACCTACGCTGGCCCTAGA, LMP1
59-AGGTTGAAAACAAAGGAGGTGACCA, LMP1 39-GGAACCAGA-
AGAACCCAAAAGCA, LMP2a 59-ATGACTCATCTCAACACATA,
LMP2a 39-CATGTTAGGCAAATTGCAAAA. To generate cDNA for
RealTime-PCR, 500 ng total RNA were reverse transcribed per 50 ll
reaction using the TaqMan Reverse Transcription Reagent (Applied
Biosystems), using the following program: 258C (10 min), followed by
508C (30 min) and 758C (5 min sec). Ampliﬁcation was performed in a
ﬁnal volume of 20 ll, containing 2 ll cDNA from the reversed
transcribed reaction, primer mixture (0.25 lM each of sense and
antisense primers), and 10 llo f2 3SYBR Green Master Mix (Applied
Biosystems). PCR was performed in ABI 7900HT Sequence Detection
System (Applied Biosystems) using following program: 958C (15 min),
followed by 40 cycles of 958C (15 sec), 558C (30 sec), and 688C (30 sec).
The ﬁnal mRNA levels of LMP1 were normalized to GAPDH using the
comparative CT method. Primers sequences for RealTime-PCR were
as follows: GAPDH 59-AGCCACATCGCTCAGACAC, GAPDH 39-
GCCCAATACGACCAAATCC, LMP1 59-AGGTTGAAAACAAAGGA-
GGTGACCA, LMP1 39-GGAACCAGAAGAACCCAAAAGCA.
NK cell cytotoxicity assay. To evaluate the cytolytic activity after
DC activation, NK cells were cocultured for 2 d with DC1s at a ratio
of 5:1 with or without blocking antibodies against IL-12 and type I
interferon receptor (anti-CD118, clone MMHAR-2, PBL Biomedical
Laboratories). The NK cell-sensitive lymphoblastoid cell line LCL
721.221, which does not express surface HLA class I molecules, was
used as target cell. Cytotoxicity assays were performed, as previously
described [28]. Brieﬂy, target cells were labeled with PKH26 (Sigma-
Aldrich, St. Louis, MO), and then incubated with NK cells at different
NK cell/target cell ratios. After 6 h, cells were harvested; TO-PRO-3, a
membrane-impermeable DNA stain, was added to each culture (1 lM
ﬁnal concentration); and cells were ﬁnally analyzed by ﬂow cytometry.
Background and maximum TO-PRO-3 staining were obtained by
incubation of target cells with medium and detergent, respectively.
The percent speciﬁc lysis was calculated as (% TO-PRO-3
þPKH26
þ
cells in NK/target cell co-culture   % TO-PRO-3
þPKH26
þ cells in
medium)/(% TO-PRO-3
þPKH26
þ cells in detergent   % TO-PRO-
3
þPKH26
þ cells in medium) 3 100%.
Statistical analysis. Statistical analyses were performed with the
paired two-tailed Student t-test. The p-value of signiﬁcant differences
is reported. Plotted data represent mean plus standard deviation
(SD), unless otherwise stated.
Supporting Information
Figure S1. NK Activation by PolyI:C-matured DCs Is IL-12 Depend-
ent and Is Mainly Restricted to CD56
brightCD16
  NK Cells
Found at doi:10.1371/journal.ppat.0040027.sg001 (158 KB PDF).
Figure S2. DC1 Induced NK Cell Proliferation and IFN-c Production
Is IL-2 Independent
Found at doi:10.1371/journal.ppat.0040027.sg002 (110 KB PDF).
Figure S3. Upregulation of NK Cell Cytotxicity by DCs Depends on
IL-12 and Type I Interferons
Found at doi:10.1371/journal.ppat.0040027.sg003 (81 KB PDF).
Figure S4. Tonsilar NK Cells Do Not Express CCR7 and Only a Low
Number Expresses CD83
Found at doi:10.1371/journal.ppat.0040027.sg004 (74 KB PDF).
Table S1. Surface Expression of DC Maturation Markers
Found at doi:10.1371/journal.ppat.0040027.st001 (74 KB PDF).
Accession Numbers
Accession numbers mentioned in this study are from Swiss-Prot
(http://www.ebi.ac.uk/swissprot/) and from GenBank (http://www.ncbi.
nlm.nih.gov/Genbank/), respectively: hIL-2, P60568; hIL-12p35,
P29459; hIL-12p40, P29460; hIL-15, P40933; hIL-15Ra, Q13261; hIL-
18, Q14116; hIFN-c, P01579; hIFNa/b-R, P17181; hCD3, P07766;
hCD16, P08637; hCD25, P01589; hCD56, P13591; hCD80, P33681;
hCD83, Q01151; hCD86, P42081; EBNA1, P03211; EBNA2, P12978;
LMP1, P03230; LMP2a, P13285; EBER1, J02078; hb-actin, P60709;
hGAPDH, P04406.
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